share_log

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $5

Benzinga ·  Jul 11 19:20

Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target from $7 to $5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment